-+ 0.00%
-+ 0.00%
-+ 0.00%

BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M

Benzinga·02/26/2026 14:08:50
Listen to the news
BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million.